Phase II study of stereotactic radiotherapy with volumetric modulated arc therapy for primary lung cancer located adjacent to organ at risk

Phase II study of stereotactic radiotherapy with volumetric modulated arc therapy for primary lung cancer located adjacent to organ at risk - Stereotactic radiotherapy for primary lung cancer located adjacent to organ at risk

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022856

Enrollment

Registered

2016-07-27

Start date

2016-07-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary lung cancer

Interventions

Perform stereotactic radiotherapy with volumetric modulated arc therapy for primary lung cancer located adjacent to organ at risk

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Pathologically or clinically diagnosed primary lung cancer. 2.tumor diameter:5 cm >= 3.tumor centrally located or located within 2cm of organ at risk 4.forced expiratory volume 1.0:700 mL <= 5.Performance status(ECOG):0-2 6.medically inoperable or patient who refused surgery 7.written informed consent

Exclusion criteria

Exclusion criteria: 1. no serious diabetes, collagen disease, cardiac disease, pulmonary disease, kidney disease and psychological disorder 2. past history or future plan of administration of molecular target drug affecting VEGF or FGF pathways 3. apparent interstitial pneumonitis or pulmonary fibrosis on CT images 4.receiving home oxygen therapy 5. Single lung 6.pregnant or lactating woman, likelihood of pregnancy 7. active infectious disease 8.implanted pacemaker or implantable cardioverter defibrillator 9. no history of thoracic radiation therapy

Design outcomes

Primary

Measure	Time frame
1-year in-field tumor control rate	—

Secondary

Measure	Time frame
1-year overall survival rate, 1-year in-field tumor control rate, the rate of 1-year adverse reaction, adverse event	—

Countries

Japan

Contacts

Public ContactSee above See above

See above See above

t.yamamoto@rad.med.tohoku.ac.jp+81-22-717-7312

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026